Systemic sclerosis & Raynaud's
Evaluation of particle-based multi-analyte technology for autoantibody detection in systemic sclerosis: concordance with conventional methods and clinical associations
Authors' conclusion
These findings support the diagnostic and clinical utility of comprehensive serological profiling and the integration of PMAT into routine diagnostic workflows.
Study context
- Population
- Systemic sclerosis (SSc) patients fulfilling the 2013 ACR/EULAR criteria, disease controls and healthy individuals
- Participants
- 124 / 205 / 25
- Comparison
- PMAT vs conventional methods for SSc-associated autoantibodies
- SScn = 124
- Disease controlsn = 205
- Healthy individualsn = 25
- Outcome
- Concordance of PMAT with conventional methods (chemiluminescence and ELISA) for SSc-associated autoantibodies
Performance
As reported in the abstract
Agreement of PMAT with established techniques
Anti-centromere autoantibodies (ACA), κ (excellent agreement)
0.95
Anti-Topo I, κ (excellent agreement)
0.95
Anti-RNApol III, κ (good agreement)
0.78
Further findings
Prevalence of autoantibodies (most prevalent)
- ACA
- 54.0%
- Anti-Topo I
- 21.0%
- Anti-RNApol III
- 5.7%
Antibody–phenotype associations
- ACA with lcSSc and absence of interstitial lung disease (ILD)
- Anti-Topo I with dcSSc, ILD and scleroderma renal crisis
- Anti-RNApol III with digital ulcers and calcinosis
- Novel: PUF60 isoform 6 with severe ILD
- Novel: PUF60 isoform 1 with sine scleroderma phenotype
Original publication
Evaluation of particle-based multi-analyte technology for autoantibody detection in systemic sclerosis: concordance with conventional methods and clinical associations. Clin Exp Rheumatol. Published 10 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →